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A crossover comparison of progression of chronic renal failure: Ke-
toacids versus amino acids. Rates of progression of chronic renal failure
were compared in patients receiving alternately an amino acid supple-
ment (AA) and a ketoacid supplement (KA) to a very low protein (0.3
g/kg), low phosphorus (7 to 9 mg/kg) diet. The first supplement was
randomly chosen. Bias due to carryover effects was minimized by
delaying the regression analysis until one month after starting or
changing supplements. In order to minimize possible bias caused by
initiating the two supplements at differing levels of severity, a multiple
crossover design was used (ABA, BAB, ABAB, or BABA) with at least
four GFR's in each treatment period (except for three GFR's in one
instance). Sixteen patients completed the protocol; five dropped out.
Average starting GFR's were nearly identical for the two supplements
(15.4 and 15.9 mI/mm). For each patient, mean progression on KA was
compared with mean progression on AA. Thirteen out of 16 patients
progressed more slowly on KA than AA. On the average, progression
on KA was significantly slower (95% confidence limits = —0.36 to 0.09
mI/mm/month) than on AA (—0.91 to —0.41 mI/mm/month; P = 0.024).
There was no significant difference in estimated protein intake, phos-
phate excretion, or mean arterial pressure between KA and AA
periods. Serum triglyceride concentration was significantly lower on
KA (P = 0.0026). 17-hydroxycorticosteroid excretion was also lower (P
= 0.031). We conclude that KA slow progression, relative to AA,
independently of protein or phosphorus intake, in patients on this
regimen.
The possibility that a low protein diet supplemented by
ketoacids might slow the progression of chronic renal failure
was first suggested by anecdotal accounts of the clinical course
of renal failure in the first patients treated in this way [1].
Several other studies have appeared, using sequential observa-
tions of creatinine clearance or reciprocal serum creatinine as
measures of progression, that support this possibility [2—111.
However, creatinine measurements have subsequently been
found to be unreliable guides to the rate of change of isotopi-
cally measured glomerular filtration rate (GFR) [12—141. Fur-
thermore, these trials, with one exception [7], have either
employed a crossover design, in which the low protein, ke-
toacid regimen is administered following a control period on a
different regimen—either protein restriction alone or more
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severe protein restriction plus a supplement of essential amino
acids [5, 6, 8]—or a non-randomized comparison of two groups
[2—4, 9—11]. Uncertainty exists in the former studies, as to how
GFR would have progressed downward if the change in therapy
had not been instituted, and in the latter, as to whether the two
groups were comparable.
Whether a very low protein diet with amino acid supplements
is effective in slowing progression also remains uncertain.
Initially, several studies appeared, in which creatinine measure-
ments were employed to assess progression, concluding that
low protein diets supplemented by essential amino acids slow
progression relative to a free diet [15, 16]. When radioisotopi-
cally measured GFR was used, however, no change in progres-
sion on initiating amino acid supplements could be found in one
of these same centers [17].
We compared progression in a small number of patients
switched from an essential amino acid supplement to a ketoacid
supplement [8]. Isotope GFR was employed only after the
change of supplements. In five cases with less advanced renal
failure, progression on ketoacids measured in this way virtually
ceased. Later, we demonstrated significantly slower progres-
sion (on the average) by sequential isotope GFR determination
in 12 patients switched from amino acids to ketoacids [18].
These results suggest a pharmacological effect of the ketoacid
supplement to slow progression, apart from whatever benefit is
obtained by protein or nitrogen restriction. However, in the
crossover studies, ketoacids were always given last.
The traditional approach to this problem is a prospective
randomized comparison of two or more groups of patients. At
least two such studies of ketoacid supplementation, using a
low-protein diet in the control group, are currently in progress
[19, 20]. Owing to the wide variability between patients in rates
of progression, large numbers of subjects must generally be
entered in such trials, at considerable expense, in order to
obtain enough statistical power.
Crossover studies are more economical. However, crossover
designs in a progressive disorder suffer not only from the
common problem of carryover effects from one treatment to
another, but also from the fact that patients may not be at the
same stage of severity when each treatment is initiated.
We have attempted to circumvent this problem by performing
multiple crossovers (two or three) in each subject. This mini-
mizes any possible differences caused by starting the two
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Table 1. Patients randomized
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14 M W 37 1 20.3 16 18 AKAK
17 M W 39 2,3 24.1 13 12 KAK
24 M W 67 3,9 10.5 15 13 AKA
25 M B 61 4,5 16.3 21 19 AKAK
26 M W 73 3,5 19.4 23 17 AKAK
33 M W 32 4 23.5 13 16 AKC
36 M W 35 3,4 24.9 17 13 KAK
38 F W 33 4 14.8 16 14 AKA
39 F W 47 3,5 13.4 29 29 AKA
42 M B 57 1,3,5 15.0 18 16 KAK
43 M W 60 4 16.5 5 4 KC
44 M W 31 1 9.6 4 5 AC
45 F W 62 5 12.5 23 20 KAKA
46 F W 79 3,4 25.2 21 17 KAKA
47 M W 34 6 15.3 19 19 AKAK
51 M W 55 3,6 23.3 24 19 KAKA
53 M W 36 1 28.9 17 15 AKA
54 F W 65 3,5 10.3 10 11 AC
56 M W 51 5,7 18.3 17 16 AKAK
57 F W 62 2 10.2 14 13 AKA
60 F W 72 8 23.9 4 5 KC
a Numbers represent: 1, diabetes; 2, polycystic kidney disease; 3, gout; 4, chronic glomerulonephritis; 5, arteriolar nephrosclerosis; 6, interstitial
nephritis; 7, analgesic nephropathy; 8, fibrillary nephritis; 9, arteriosclerosis,b A, amino acids; K, ketoacids
C Dropped out
supplements at differing levels of severity and provides more
power to distinguish between a nonlinear trend in GFR progres-
sion and the effects of a treatment switch. Bias due to possible
carryover effects was reduced or eliminated by estimating
progression rates, following a change in treatment, only after a
month had elapsed. The results indicate a significant effect of
ketoacid supplements in slowing progression, compared with
amino acid supplements to the same low protein diet.
Methods
The following protocol was approved by the Joint Committee
on Clinical Investigation of the Johns Hopkins Medical Institu-
tions.
Twenty-one patients were selected for study (Table 1). None
of these patients participated in previous studies from this
laboratory [8, 18]. Criteria for inclusion and exclusion are given
in Table 2. After informed consent was obtained, patients were
randomized, using a table of random numbers, by a third party
not involved in the study, to receive as their initial dietary
supplement either a mixture of essential amino acids (AA) or a
mixture of ketoacids and amino acids (KA).
Composition of these mixtures was previously reported [81.
KA was obtained as "CSW2OI4" from Sylatec/Clintec Technol-
ogies, Tours, France, and supplied as coated tablets. AA was
compounded by the Johns Hopkins Hospital Pharmacy and
supplied as gelatin capsules. Dosage of AA was 10 g daily in
divided doses with meals, providing 1.1 g N per day. Dosage of
KA was 2.8 g per nearest 10 kg of ideal body weight, in divided
doses with meals, providing 0.28 g N/l0 kg. The reason for
varying the dosage of KA but not AA with body weight was that
Table 2. Patient inclusion and exclusion criteria
Inclusion criterion
Chronic renal failure, as defined by a subnormal glomerular
filtration rate (GFR) in the absence of acute renal failure.
Exclusion criteria
I. Age less than 18 or over 75 years.
2. Pregnant or planning to become pregnant.
3. Compliance doubtful owing to drug abuse, alcohol abuse,
psychiatric illness, poor understanding of study, limited
motivation, transient residence, or unsuitable home
environment.
4. Impaired nutrition, as evidenced by body weight less than 85%
or more than 150% of standard weight, serum albumin less than
3.5 g/dl or serum transferrin less than 180 mg/dl.
5. Proteinuria greater than 10 g/day.
6. Presence of urinary tract obstruction, vesicoureteral reflux grade
III or worse, branched or staghorn calculi, kidney transplant, or
cystinuria.
7. Chronic serious medical condition such as malignancy, severe
heart failure, collagen vascular disease, or any other condition
leading to frequent hospitalization or severe disability.
8. Immunosuppressive drugs, gold, penicillamine, frequent doses
of salicylates or non-steroidal anti-inflammatory drugs, or any
investigational new drug.
9. Inability to empty the bladder.
no pharmacological effects of AA have ever been reported; they
serve only to correct for the otherwise inadequate intake of
essential amino acids from the diet. On the other hand, KA
have been reported to exert a number of effects beyond serving
as precursors to essential amino acids [21]. Consequently we
felt it was appropriate to vary dosage with body weight. Ideal
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body weight was employed rather than actual body weight
because metabolically active body cell mass is more closely
related to ideal body weight.
Following randomization, patients were instructed by one of
us (L.W.) on the diet. Caloric prescription was derived from
three-day diet diaries, a 24-hour diet recall and an estimate of
basal energy expenditure adjusted for activity. Average caloric
intake was 35 kcal per kg of actual body weight, except that in
cases where weight loss was desirable, total intake was reduced
by 500 to 1000 calories per day. Mixed quality protein was
prescribed at 0.3 glkg ideal body weight. Phosphorus was
prescribed at 7 to 9 mg per kg ideal body weight. All patients
received a low protein exchange list, sample menus and a
cookbook containing patient-developed low protein recipes. To
meet caloric needs it was necessary to include extra fats, simple
sugars, and low protein specialty products. However, the
intake of fat did not exceed 30% of the total caloric intake.
Simple sugars as soft drinks and candy provided additional
calories. The acceptance of low protein specialty products
varied among patients. Average dietary potassium was 65
mEq/day, except when hyperkalemia occurred; in these in-
stances potassium intake was decreased slightly, and a potas-
sium-binding resin (sodium polystyrene sulfonate) was pre-
scribed. All patients consumed a vitamin-mineral preparation
(Theragran M), one tablet per day. A total of 1000 mg of
supplemental elemental calcium was prescribed as CaCO3.
Follow-up was provided by phone or at clinic visits whenever
requested by the physician, patient, or dietician.
Compliance with the dietary protein prescription was as-
sessed from measurements of 24-hour urinary urea N at each
visit. When this value exceeded its target (Results), patients
were referred for additional dietary counseling and exhorted as
to the importance of compliance with the diet. When both
urinary phosphate excretion and plasma phosphate were rela-
tively high, dietary counseling regarding possible dietary
sources of phosphorus was provided. Compliance with the
supplements prescribed was informally assessed by questioning
the patients; pill counts were not conducted.
By random assignment, 13 patients received AA first and 8
patients received KA first (Table 1). Patients were seen
monthly, on the average, although the interval between visits
varied from three to six weeks. This was because patients
progressing rapidly, such as #14, were seen slightly more
frequently, whereas one patient (#26) missed several appoint-
ments.
At each visit patients brought in a 24-hour urine collection
and arrived fasting, or in a few cases (mostly diabetics), after a
light breakfast.
Body weight was measured without shoes. Blood pressure
was measured in the sitting posture, except where there was a
question of postural hypotension, in which case blood pressure
was also measured in the supine posture. Anti-hypertensive
drugs (including angiotensin-converting enzyme inhibitors, em-
ployed in the last two periods in patient #38 and all three
periods in patient #53), diuretics, allopurinol, colchicine and
NaHCO3 were prescribed as indicated.
GFR was measured at each visit. GFR values were not
corrected for body size except for screening purposes. Follow-
ing an oral water load of 10 to 15 mI/kg, 100 Ci 99mTclabeled
diethylenetriamine-pentaacetic acid was injected intravenously.
Beginning 60 minutes later, three timed urine collections with
blood samples at the beginning and end of each period were
obtained. Studies in which urine flow was judged inadequate,
based on criteria reported elsewhere [22, 23], were repeated.
Two patients had one GFR each rejected on this basis.
At each visit, blood samples for routine chemical and hema-
tological determinations were performed in the Johns Hopkins
Hospital Chemistry and Hematology Laboratories, using auto-
mated methods. Twenty-four-hour urine was analyzed for pro-
tein, phosphate, and urea N by the Chemistry Laboratory.
Excreted/filtered phosphate was calculated as 24-hour urinary
phosphate/(plasma phosphate, mg/l x GFR, 1/day).
After four GFR's, least squares linear regression slope of
GFR on time in months was calculated. If the slope was
positive, crossover was deferred and GFR measurements were
continued at monthly intervals until the slope became negative
or until two years elapsed. This deferral permitted patients to
continue receiving therapy that appeared to be effective. As
soon as a negative slope was estimated (based on at least four
GFR's), the supplement was switched. Calculation of the new
slope after a change of supplement began with the first GFR
after switching, that is, one month later. This process was
repeated until at least three periods of 4 GFR's each were
completed. As noted below, five patients failed to complete this
protocol. If the second treatment was associated with slower
progression, patients were switched back to it for four more
GFR's in a fourth period of observation.
The effects of treatment on GFR progression, chemical
measures, and blood pressure were calculated separately for
each patient by taking the difference between the patient's
average value during KA and the average value during AA
periods. As noted, the GFR progression outcomes were calcu-
lated using least squares regression. These patient-specific
estimates were then analyzed by standard methods (t-test,
Wilcoxon signed rank test) [24].
Pooled mean square error about the regression lines of GFR
versus time was 2.05 (ml/min/month)2.
In a second approach to the analysis, a linear random effects
model was postulated [25] and restricted maximum likelihood
estimates were found using an "EM" algorithm [26].
Results
Drop-outs
Patient #33, randomized to AA, progressed at —0.501 mlI
mm/month. After switching to KA, he did not progress for two
months, then his GFR suddenly fell 60%. This was confirmed
on two repeat determinations. No cause could be found. He
declined to continue the study and obtained a renal transplant.
The effect of including his results is considered in the Discus-
sion. Patient #43, a 60-year-old man with biopsy-proven gb-
merulonephritis, randomized to KA, developed Goodpasture's
syndrome and died. Patient #44, a 31-year-old insulin-depen-
dent diabetic with a pre-treatment GFR of 9.6 mb/mm, was
randomized to amino acids. His GFR fell at 1 mb/mm/month and
he was started on dialysis four months later. Patient #54, a
65-year-old woman with gout and hypertension, had an initial
GFR of 10.3 mi/mm. Randomized to AA, she at first exhibited
no progression but then went downhill. Dialysis was begun.
Patient #60, a 72-year-old woman with biopsy-proven fibriblary
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Fig. 1. Sequential GFR vidues in 16 patients alternately given supplements of amino acids (A) or ketoacids (K). Linear regression lines are shown.
nephritis, was withdrawn by her daughter after five GFR's on
KA, the last value being 17.8 mllmin.
All three periods of patient #24 are included in the analysis
even though a fourth GFR was not obtained in his third
treatment period, owing to his death from myocardial infarc-
tion; no apparent change in his clinical condition preceded this
fatal event.
Comparison of randomized groups
There were no major differences between the ten patients
completing the protocol who were randomized to receive AA
first and the six randomized to receive KA first with respect to
gender, age, or initial GFR.
Postponements
As noted in the Methods section, crossovers were postponed
whenever the estimated rate of change of GFR was positive
rather than negative (ignoring statistical significance), for a
maximum of two years. This occurred in eight periods on KA
supplements and in seven periods on AA supplements. As
shown in Figure 1, patient #39 remained on KA for two years
without progression.
Side effects
No side effects of either supplement were observed.
Nutritional parameters
One patient (#46) was hypoalbuminemic throughout the
study (3.1 to 3.3 gIdl), but her serum transferrin concentration
was normal (248 to 263 mgldl). One patient (#47) exhibited a
slightly subnormal transferrin (175 to 187 mgldl) but a normal
albumin concentration (4.5 to 4.8 gIdl). Hypercholesteremia and
hypertriglyceridemia were both common, as was anemia. Body
weight (not shown) did not change.
None of these parameters differed significantly between the
two supplements (Table 3) except serum triglyceride concen-
tration, which was 31 mgldl lower (P = 0.0026) on KA than on
AA. The high level of significance of this relatively small (15%)
change is a reflection of the statistical power of this repeated
crossover design.







0 4 8 12 0 5 10 15
#36 35 WM #38 33 WM
.— #i'h _____


























#42 57 BM #4562WF #46 79 WF #47 34 WM
0 10 20 30
0 5 10 15 20
#51 55 WM
0 5 10 15 20
#5334 WM
I.














10 20 0 5 10 15 0 4 8 12 16 0 5 10 15
1
Time, months Time, months
Walser et a!: Progression of chronic renal failure 937
Table 3. Mean values SD during each supplement
Supplement
PAA KA
GFR, mI/mm 15.8 5.6 15.6 6.8 NS
Progression, mI/mini —0.67 0.42 —0.15 0.62 0.024
month
Blood pressure, mm Hg
Systolic 146 12 146 13 NS
Diastolic 86 7 86 7 NS
Mean 105 6 107 7 NS
Hematocrit, % 34 3 33 4 NS
Serum
Urea N, mg/dl 41 16 43 16 NS
Creatinine, mg/dl 4.0 1.5 4.0 1.7 NS
Albumin, g% 4.4 0.4 4.4 0.5 NS
Transferrin, mg/dl 252 41 254 50 NS
Uric acid, mg/dl 8.5 1.8 8.4 1.0 NS
Calcium, mg/dl 9.0 0.5 9.0 0.4 NS
Phosphate, mg/dl 4.0 0.7 4.1 0.9 NS
Ca x P, mg2/d12 36 7 37 9 NS
Cholesterol, mg/dl 214 60 206 55 NS
LDL cholesterol, mg/dl 127 52 126 51 NS
HDL cholesterol, mg/dl 38 14 38 15 NS
Triglycerides, mg/dl 242 119 209 83 0.0021
24-Hr urine
Urea N, g/day 5.0 1.3 5.2 1.2 NS
Protein, glday 1.8 1.6 1.7 1.4 NS
Phosphate, mg/day 403 119 380 128 NS
Excreted/filtered P 0.49 0.18 0.47 0.19 NS
17-hydroxycortico- 4.2 1.8 3.4 0.9 0.031
steroids, mg/day
Compliance
Target values for urinary urea N were calculated as dietary
protein prescription x 0.16 plus supplement N content minus 31
mg N/kg (for N excretion in forms other than urea [27]) minus
urinary protein x 0.16. The difference between measured
urinary urea N and target urinary urea N ÷ 0.16 represents
dietary protein ingested in excess of prescribed. Actual dietary
protein estimated in this way averaged 0.45 g!kg, instead of 0.3
glkg as prescribed. Thus dietary compliance was relatively
poor. However, protein intake before starting dietary therapy,
estimated in 16 of these patients from 24-hour urinary urea N,
was considerably higher (mean SD = 0.82 0.20 g/kg).
No patients admitted to failing to consume the supplements,
except during intercurrent illnesses, such as upper respiratory
infections.
Blood pressure
Mean arterial pressure averaged 107 mm Hg during KA
supplementation and 105 mm Hg during AA supplementation
(Table 3). These values do not differ significantly, nor do values
for mean systolic or diastolic pressure.
Renal function
GFR, serum urea N, and serum creatinine did not differ
between AA and KA (Table 3).
Progression
The rate of change of GFR during KA averaged —0.15
ml/min/month, while the rate of change of GFR during AA
averaged —0.67 ml/min/month (Table 4). The estimate of the
difference in progression rates is therefore 0.52 0.18 (sEM)










14 —0.679 —0.912 0.232
17 —0.201 —1.796 1.595
24 —0.083 —0.532 0.449
25 0.650 —0.387 1.038
26 —0.109 —1.000 0.891
36 0.754 —1.031 1.785
38 —0.578 —1.088 0.510
39 0.027 —0.634 0.662
42 —0.054 —0.644 0.590
45 —0.152 —0.373 0.222
46 —1.375 —0.217 —1.158
47 —0.441 —0.600 0.160
51 —0.078 —0.297 0.220
53 —0.910 —0.292 —0.618
56 1.092 —0.769 1.860
57 —0.225 0.015 —0.240
Table 5. Estimated expected progression rates, mi/mm/mo, based on
the random effects model
Parameter Estimate 95% Confidence limits
Rate of progression on KA —0.14
—0.36, 0.09
Rate of progression on AA —0.66
—0.91, —0.41
Difference, KA-AA 0.52 0.21, 0.84
Change in GFR during first 0.12
—0.82, 1.08
month after switching
from KA to AA
Change in GFR during first 0.13
—0.77, 1.02
month after switching
from AA to KA
mI/mm/month (P = 0.024 by t-test). Using Wilcoxon's signed
rank test [24], P < 0.05.
Mean period-to-period differences in progression rates, KA-
AA, were all of the same sign but failed to achieve statistical
significance individually: period 1 to period 2, 0.29 0.15
ml/min/month, P = 0.07; period 2 to period 3, 0.38 0.27
mi/mm/month, P = 0.18; period 3 to period 4, 0.79 0.47
mlimin/month, P = 0.14. Mean difference between slopes on
the same treatment (period 1 vs. period 3 or period 2 vs. period
4) were not significant. These differences presumably reflect the
error of measurement. No relationship between rate of progres-
sion and clinical condition was apparent.
We also modelled GFR progression over time using a linear
random effects regression model which allowed four distinct
rates of progression: (1) treatment AA, (2) treatment KA, (3)
first month on AA after switching from KA, (4) first month on
KA after switching from AA. All terms were modeled as
random effects (Table 5). Consistent with the first analysis, the
expected progression rate during AA periods was estimated as
—0.66 mllmin/month (95% confidence interval —0.91, —0.42).
The expected progression rate during KA was estimated as
—0.14 ml/min/mo (95% confidence interval —0.36, 0.09). The
expected difference in progression rates was 0.52 mllmin/month
(95% confidence interval 0.21, 0.84).
Very similar results were obtained when a quadratic term of
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follow-up time squared was added to the regression model to
allow for the possibility of individual secular trends.
Discussion
In summary, we found that when 16 patients were alternately
provided with KA or AA supplements for three or four treat-
ment periods, 13 of them exhibited slower progression on KA
supplements and three exhibited slower progression on AA
supplements. This difference is statistically significant. One
further patient (#33) had observations during two treatment
periods, but he failed to complete the three period protocol.
Even if this patient is included, so that 13 out of 17 progress
more slowly on KA, this result remains significant (P <0.05) by
the sign test [241.
In the 16 subjects who completed the protocol, mean pro-
gression rate on KA is only 22%of that on AA. This difference,
if projected to a final GFR of 6 mllmin (a typical value for the
initiation of dialysis), would predict postponement of the need
for dialysis for many years. Since the patients were only
followed for a few months on each supplement, extrapolation to
time of dialysis from these data is hazardous. However, the
protocol was designed so that each patient would end by
receiving the supplement that was associated with a slower rate
of progression. Long-term follow-up on the final supplement
has been carried out in seven of these patients (#25, #36, #42,
#47, #51, #53 and #56), two on AA and five on KA, for an
average of 14 months following the completion of the present
protocol. Most recent GFR's in these seven patients are, on the
average, 97 17% (SD) of last GFR's during the protocol,
shown in Figure 1. Thus it appears that long-term arrest of
progression predicted by these repeated crossover results is
borne out.
It is difficult to conceive an effect of ketoacid or amino acid
supplements on chronic renal failure that could persist more
than a month after withdrawing the supplement. Hence our
method of analyzing the data should eliminate bias due to
carryover effects.
The patients who progressed more slowly on AA (#46, #53,
and #57) do not differ in any obvious way from the others. Thus
it is not possible from these limited observations to predict
which patients will respond more favorably to one supplement
or the other. Nevertheless, the results suggest that use of the
ketoacid-supplemented regimen in all patients would increase
the average time to dialysis by many years. However, only a
long-term randomized study without crossovers can establish
this point.
These results do not shed any light on the efficacy of AA
supplements, in comparison with an unsupplemented diet, on
the progression of renal failure.
There is a highly significant correlation (r
—0.674, P =
0.004) between the treatment effect of KA, as shown in Table 4,
and the progression rate on AA. Thus more rapidly progressing
subjects exhibit a larger treatment effect of KA. This is impor-
tant from the practical point of view as well as from the point of
view of study design and statistical analysis. Perhaps a model
which postulates that KA effects a percentage change in rate of
progression is to be preferred over assumption of an absolute
change. However, regression towards the mean could be a
factor in producing this correlation.
An important inference from this study is that statistically
significant results can be obtained concerning effects of any
agent on progression with relatively small numbers of patients
(providing the effect is sufficiently large). This conclusion
contradicts the view that hundreds of patients must be studied,
at enormous cost, in order to assess the effect of any experi-
mental variable on rate of progression. Multicenter trials now in
progress [19, 20] are based on this latter view, even though one
of them [19] includes a crossover design ("Study C"). While
non-crossover studies are more universally accepted, it is clear
that progress in this field will be far more rapid if crossover
studies can be viewed as providing statistically valid informa-
tion.
The mechanism by which ketoacids slowed progression is not
apparent from these data. Estimated protein intake, blood
pressure, and severity of renal insufficiency did not differ
significantly between the two supplements. 17-Hydroxygluco-
corticoid excretion, which we previously found to be correlated
with progression rate and to be reduced by KA supplements
[281, was measured in 208 of the 270 samples of the present
study. It fell 19% (P = 0.031) on KA. Serum triglyceride
concentration was significantly lower on KA supplements. This
could be a factor in the change in progression, since hyperlip-
idemia has been identified as an important contributor to
progression in patients [29]. However, there was no correlation
between period-to-period change in triglyceridemia and change
in progression.
Salahudeen, Clark and Nath [30] have suggested that ketoac-
ids may lessen renal injury by an antioxidant mechanism. We
have recently observed that continuous intravenous infusion of
2-ketoisocaproate in septic rats significantly reduces plasma
and whole blood ratios of oxidized/total glutathione (Yonekura,
Matsusue, and Walser, unpublished observations). In addition,
we found that plasma nitrate elevation in these animals is
markedly attenuated, suggesting that 2-ketoisocaproate may
also suppress the induction by sepsis of nitric oxide production.
The roles of oxygen free radicals and of nitric oxide in progres-
sion of chronic renal failure remain to be clarified.
Our patients were probably more motivated and compliant
than average. Hence, it remains to be determined whether
nutritional therapy of this type, even if efficacious, would be
acceptable to the general population of patients with chronic
renal failure.
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